Stock Update: Abbott Laboratories (NYSE:ABT) – Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes

[PR Newswire] – ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ — Abbott (ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary . . . → Read More: Stock Update: Abbott Laboratories (NYSE:ABT) – Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes Similar Articles: Company Update (NYSE:LLY): Type 2 diabetes: Jentadueto® (linagliptin and metformin hydrochloride) tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C Market Update (NYSE:ABT): Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo Company Update (NYSE:GE): Leading forensic laboratories participate in independent validation of the GE Healthcare Life Sciences and NetBio Rapid DNA system